Fri Dec 28, 2012 10:47am EST
(Reuters) – Watson Pharmaceuticals Inc pronounced on Friday it has practical for U.S. capitulation to marketplace a general chronicle of Velcade, a diagnosis for mixed myeloma done by Takeda Pharmaceutical Co.
Takeda’s Millennium section filed a lawsuit final week opposite Watson’s Actavis unit, seeking to forestall Actavis from offered general Velcade before to a death of certain U.S. patents.
Drug companies that record lawsuits opposite general manufacturers that plea their patents are typically postulated a insurance duration of adult to 30 months from a date of a general drugmaker’s filing for capitulation of a possess drug.
Velcade, that generated sales of $740 million in a 12 months finished October, is one of a heading treatments for mixed myeloma.
(Reporting By Toni Clarke; modifying by John Wallace)
Source: Health Medicine Network